That is a really good question "really people"!!
Post# of 151626

If our s/c interim analysis data showed 70% reduction in deaths vs SOC + placebo, would the DSMC have recommended a halt to the trial, with placebo folks being then, given leronlimab?
Or....... do they strictly and only consider the calculated p value?
I'm not that informed about p value calculation, but with 70% reduction in deaths, would that very probably have resulted in a great p value and a recommended halt in the trial??
I was also scolded here, advised that I should ask questions and not make statements....(4 questions above).

